Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAN-STAMP: Radiation and Niraparib in Serous/p53 Mutant Endometrial Cancer
NCT04159155Phase 3Terminated
- Sponsor
- University Health Network
- Start
- Nov 2020
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of niraparib in endometrial carcinoma, sponsored by University Health Network. Started Nov 2020; status: terminated.
02
Drugs
niraparib
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT04159155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04159155.